Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Johnson & Johnson (NYSE: JNJ) announced that nipocalimab received U.S. FDA Fast Track designation for adults with systemic lupus erythematosus (SLE) on March 3, 2026. The designation recognizes unmet need and may expedite development and review timelines.
Nipocalimab showed reduced lupus disease activity and potential steroid-sparing in a Phase 2 study (JASMINE), and Johnson & Johnson is enrolling adults in the Phase 3 GARDENIA study.
Johnson & Johnson (NYSE: JNJ) said nipocalimab received U.S. FDA Fast Track designation for adults with systemic lupus erythematosus (SLE) on March 3, 2026. The designation reflects unmet need and may accelerate review. A Phase 2b (JASMINE) showed reduced lupus disease activity and steroid-sparing potential; Phase 3 (GARDENIA) enrollment is underway.
Johnson & Johnson (NYSE: JNJ) will host an investor conference call to discuss first-quarter results at 8:30 a.m. ET on Tuesday, April 14, 2026. Joaquin Duato, CEO; Joseph Wolk, CFO; and Darren Snellgrove, VP Investor Relations, will host and additional executives will join the Q&A.
The webcast and presentation materials will be available at www.investor.jnj.com. A replay will be posted about three hours after the call and remain available until approximately 12:00 a.m. on April 28, 2026. U.S. dial-in numbers and international numbers are provided for live participation and replay; the replay conference ID is 13759017. The press release will be available at about 6:45 a.m. ET on the morning of the call.
Johnson & Johnson (NYSE:JNJ) reported preliminary Phase 1b results showing the bispecific T-cell engager pasritamig plus docetaxel produced deep, durable PSA reductions and a safety profile consistent with docetaxel alone. Among 51 patients, PSA declines ≥50% occurred in 64.7% overall and 75.0% of taxane-naïve patients. No cytokine release syndrome or treatment-related deaths were observed. The program is advancing into Phase 3 studies, with two trials ongoing and regulatory designations in China and the U.S.
Johnson & Johnson (NYSE: JNJ) submitted an sBLA to the FDA on Feb 24, 2026, seeking approval of IMAAVY (nipocalimab) as the first treatment for warm autoimmune hemolytic anemia (wAIHA).
Phase 2/3 ENERGY showed a rapid, durable hemoglobin response and improved fatigue versus placebo; IMAAVY was generally well tolerated. Full ENERGY results are forthcoming.
Johnson & Johnson (NYSE: JNJ) reported long-term QUASAR LTE results showing sustained TREMFYA (guselkumab) benefit through Week 140 in adults with moderately to severely active ulcerative colitis. At Week 140, 80.8% were in clinical remission, 78.6% achieved histo-endoscopic mucosal improvement, and 53.6% reached endoscopic remission.
About 89% of eligible participants completed treatment through Week 140, 87.5% of Week 44 remitters stayed in remission through Week 140, efficacy held regardless of prior biologic/JAK history, and no new safety concerns were observed.
Johnson & Johnson (NYSE:JNJ) reported Phase 1b/2 OrigAMI-4 results showing first-line subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus pembrolizumab produced a 56% confirmed overall response rate (22/39) and a 10% complete response rate in PD-L1-positive, HPV-unrelated recurrent or metastatic HNSCC.
Median follow-up was 10.4 months; median PFS was 7.7 months and median OS was not estimable. Safety matched known profiles with no new signals.
Johnson & Johnson (NYSE: JNJ) announced a more than $1 billion investment in a next‑generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. The site is expected to create >4,000 construction jobs and >500 biomanufacturing jobs and is part of a $55 billion U.S. investment through early 2029.
This expands JNJ’s Pennsylvania footprint, supporting its roughly $10 billion annual economic impact and adding to ten statewide facilities totaling more than 2 million square feet.
Johnson & Johnson (NYSE: JNJ) announced that the U.S. FDA granted Breakthrough Therapy Designation on Feb 18, 2026 for subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as monotherapy for adults with recurrent or metastatic, HPV-unrelated head and neck squamous cell carcinoma after platinum and PD-1/PD-L1 therapy.
The designation is based on Phase 1b/2 OrigAMI-4 data showing rapid, durable responses in a heavily pretreated population; a Phase 3 OrigAMI-5 trial is ongoing.
Johnson & Johnson (NYSE: JNJ) announced FDA approval of a new monthly dosing schedule for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combined with oral LAZCLUZE for first-line EGFR-mutated advanced NSCLC, available as early as Week 5.
The approval preserves established efficacy and safety versus the bi-weekly subcutaneous schedule, shows pharmacokinetic comparability to prior IV and SC regimens, and reports a fivefold reduction in administration-related reactions versus historical IV delivery.